Sarepta therapeutics names louise rodino-klapac, ph.d., head of research and development

Cambridge, mass., nov. 17, 2021 (globe newswire) -- sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced that, effective immediately, louise rodino-klapac, ph.d., executive vice president and chief scientific officer, has been named the company's head of research and development (r&d) and will continue to serve in the role of chief scientific officer. gilmore o'neill, m.b., m.m.sc., who has served as head of r&d since 2018, will leave the company at the end of november and remain in a consulting capacity until march 31, 2022.
SRPT Ratings Summary
SRPT Quant Ranking